Is NSMP Truly a "Wastebox" Group? Identifying Homogeneous Subgroups Within This Heterogeneous Category-Recording

Video Transcription

Video Summary

The presentation sheds light on the role of the NSMP (No Specific Molecular Profile) group in endometrial cancer, arguing it is more of a treasure trove than a waste box due to its potential valuable insights. A clinical scenario is introduced about a postmenopausal woman with stage 2A endometrial cancer, categorized as NSMP based on IHC profiling. This group shows significant molecular and histological heterogeneity. While much of NSMP is low-grade endometrioid type, aggressive variants exist, which complicate prognosis. L1-CAM and estrogen receptor (ER) expression emerge as key prognostic markers, with ER positivity indicating better outcomes. Current research emphasizes the importance of differentiating these markers for precise treatment planning. The potential of AI in recognizing histopathological subtypes is also mentioned. The ongoing ORANGE NSMP trial aims to refine treatment approaches based on ER status. The presentation concludes with the recommendation for a multidisciplinary approach for tailoring treatment plans.

Keywords

NSMP endometrial cancer

prognostic markers

estrogen receptor

AI histopathology

ORANGE NSMP trial